MiNK Therapeutics (INKT)

Executive Summary

MiNK Therapeutics is a clinical-stage biotechnology company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead candidate, agenT-797, has completed Phase 1 trials in solid tumors (in combination with checkpoint inhibitors), relapsed/refractory multiple myeloma, and acute respiratory distress syndrome (ARDS). The platform leverages a dual mechanism combining NK cell cytotoxicity with T cell memory, enabling administration without lymphodepletion or HLA matching. With a market capitalization of approximately $56 million, MiNK is undervalued relative to its potential. The company is poised to advance agenT-797 into Phase 2 studies and may seek strategic partnerships to accelerate development. Key upcoming catalysts include the initiation of a Phase 2 trial in solid tumors, potential partnership announcements, and updates on the ARDS program.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 trial for agenT-797 in solid tumors70% success
• Q2 2027Strategic partnership or licensing deal for agenT-79750% success
• Q1 2027Clinical update or Phase 2 start for ARDS program60% success